Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnett, H.J.M.
Right arrow Articles by Eliasziw, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnett, H.J.M.
Right arrow Articles by Eliasziw, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
Medline Plus Health Information
*Blood Thinners

(Stroke. 1996;27:588-592.)
© 1996 American Heart Association, Inc.


Articles

Aspirin Dose in Stroke Prevention

Beautiful Hypotheses Slain by Ugly Facts

H.J.M. Barnett, MD; M. Kaste, MD; H. Meldrum, BA M. Eliasziw, PhD

From the John P. Robarts Research Institute, London, Ontario (H.J.M.B., H.M.), and the Department of Epidemiology and Biostatistics, University of Western Ontario (Canada) (M.E.); and the Department of Neurology, Helsinki (Finland) University Hospital (M.K.).

Correspondence to H.J.M. Barnett, MD, The John P. Robarts Research Institute, PO Box 5015, 100 Perth Dr, London, Ontario, Canada N6A 5K8.


Key Words: aspirin • platelet aggregation • stroke prevention


*    Introduction
 
Thomas Huxley wrote: "The great tragedy of Science—the slaying of a beautiful hypothesis by an ugly fact."1 Acceptance of several hypotheses has convinced many clinicians to use low-dose aspirin whenever thrombosis or thromboembolism arising in any critical arterial systems threatens vital organs. Two current communications support this concept.2 3 This editorial reflects upon the possibility that this insistence on low dose is not based on unassailable data and could have tragic consequences for stroke prevention.

In the 1950s, the role of platelet-fibrin emboli was identified in patients with transient ocular and cerebral ischemic events.4 In 1965 and 1967 two drugs, sulfinpyrazone and aspirin, were observed to alter functions of blood platelets.5 6 Harrison et al7 reported on two patients whose attacks of frequent amaurosis fugax stopped with administration of 600 mg aspirin. Within 2 to 4 days the attacks would recur when the aspirin was replaced by either placebo or 150 mg dypyridamole. The mechanisms of action of aspirin on platelets or endothelial cells were not elucidated when the Canadian Cooperative Study group launched the first randomized trial using aspirin in thrombosis prevention. We selected an arbitrary dose of aspirin based on the dosage commonly used in pain relief and convenient to put in capsule form. The sulfinpyrazone dose used was the same as that for antigout therapy. The study design was double-blind 2x2 factorial; look-alike capsules of 325 mg aspirin, 200 mg sulfinpyrazone, both, or placebo were given four times daily.8

Subsequent trials were launched involving patients with TIA and nondisabling . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, et al.
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance".
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 667 - 677.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 199S - 233S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 234S - 264S.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
A. T. Collaboration
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
BMJ, January 12, 2002; 324(7329): 71 - 86.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth
Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Chest, January 1, 2001; 119 (2009): 39S - 63S.
[Full Text] [PDF]


Home page
StrokeHome page
R. L. Hughes, G. W. Albers, R. G. Hart, H. L. Lutsep, D. W. Newell, and R. L. Sacco
Supplement to the AHA Guidelines for the Management of Transient Ischemic Attacks • Response to Dr Hughes:
Stroke, April 1, 2000; 31 (4): 983 - 991.
[Full Text]


Home page
StrokeHome page
G. W. Albers, R. G. Hart, H. L. Lutsep, D. W. Newell, and R. L. Sacco
Supplement to the Guidelines for the Management of Transient Ischemic Attacks : A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association
Stroke, November 1, 1999; 30(11): 2502 - 2511.
[Full Text] [PDF]


Home page
Arch NeurolHome page
J. L. Wilterdink and J. D. Easton
Dipyridamole Plus Aspirin in Cerebrovascular Disease
Arch Neurol, September 1, 1999; 56(9): 1087 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
E. S. Johnson, S. F. Lanes, C. E. Wentworth III, M. H. Satterfield, B. L. Abebe, and L. W. Dicker
A Metaregression Analysis of the Dose-Response Effect of Aspirin on Stroke
Arch Intern Med, June 14, 1999; 159(11): 1248 - 1253.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. M. Bednar and C. E. Gross
Antiplatelet Therapy in Acute Cerebral Ischemia
Stroke, April 1, 1999; 30(4): 887 - 893.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
H. K. Breddin
Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 87 - 95.
[Abstract] [PDF]


Home page
CirculationHome page
J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al.
Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association
Circulation, February 10, 1998; 97(5): 501 - 509.
[Full Text] [PDF]


Home page
StrokeHome page
F. Masuhr, M. Busch, and K. M. Einhaupl
Differences in Medical and Surgical Therapy for Stroke Prevention Between Leading Experts in North America and Western Europe
Stroke, February 1, 1998; 29(2): 339 - 345.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al.
Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association
Stroke, February 1, 1998; 29(2): 554 - 562.
[Full Text] [PDF]